Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.24
+0.06 (0.97%)
At close: Jun 8, 2026, 4:00 PM EDT
6.32
+0.08 (1.28%)
After-hours: Jun 8, 2026, 5:49 PM EDT
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $83.13M in the quarter ending March 31, 2026, with 38.27% growth. This brings the company's revenue in the last twelve months to $314.85M, up 41.47% year-over-year. In the year 2025, Xeris Biopharma Holdings had annual revenue of $291.85M with 43.72% growth.
Revenue (ttm)
$314.85M
Revenue Growth
+41.47%
P/S Ratio
3.42
Revenue / Employee
$723,800
Employees
435
Market Cap
1.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 291.85M | 88.78M | 43.72% |
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Phibro Animal Health | 1.50B |
| Evotec SE | 859.03M |
| Collegium Pharmaceutical | 796.33M |
| Pacira BioSciences | 734.86M |
| Amphastar Pharmaceuticals | 720.53M |
| Alvotech | 562.04M |
| Esperion Therapeutics | 418.24M |
| Harrow | 268.68M |
XERS News
- 5 days ago - Xeris Biopharma Holdings Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Xeris Biopharma Holdings Earnings release: Q1 2026 - Filings
- 4 weeks ago - Xeris Biopharma Holdings Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Xeris Biopharma Reports First Quarter 2026 Financial Results - Business Wire
- 6 weeks ago - Xeris Biopharma Holdings Proxy statement: Proxy filing - Filings
- 6 weeks ago - Xeris Biopharma Holdings Proxy statement: Proxy filing - Filings
- 6 weeks ago - Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire